Mamta K. Jain
A5072031668- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- COVID-19 Clinical Research Studies
- HIV-related health complications and treatments
- SARS-CoV-2 and COVID-19 Research
- HIV Research and Treatment
- Long-Term Effects of COVID-19
- HIV, Drug Use, Sexual Risk
- Pneumocystis jirovecii pneumonia detection and treatment
- Liver Disease and Transplantation
- Hepatitis Viruses Studies and Epidemiology
- Respiratory viral infections research
- Influenza Virus Research Studies
- Immune Cell Function and Interaction
- Healthcare cost, quality, practices
- Systemic Lupus Erythematosus Research
- COVID-19 and healthcare impacts
- Viral-associated cancers and disorders
- Adolescent Sexual and Reproductive Health
- Otolaryngology and Infectious Diseases
- SARS-CoV-2 detection and testing
- Hepatocellular Carcinoma Treatment and Prognosis
The University of Texas Southwestern Medical Center
2016-2025
Southwestern Medical Center
2016-2025
Garden City Community College
2025
Parkland Health & Hospital System
2015-2024
Parkland Memorial Hospital
2024
Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences
2023
Australian National University
2022
University Medical Center
2020
University of Copenhagen
2020
Rigshospitalet
2020
BackgroundSevere coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment baricitinib, a Janus kinase inhibitor, plus remdesivir are not known.MethodsWe conducted double-blind, randomized, placebo-controlled trial evaluating baricitinib in hospitalized adults Covid-19. All the patients received (≤10 days) and either (≤14 or placebo (control). primary outcome was time to recovery. key secondary clinical status at day 15.ResultsA...
BackgroundLY-CoV555, a neutralizing monoclonal antibody, has been associated with decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients coronavirus disease 2019 (Covid-19). Data are needed on effect this antibody patients who hospitalized Covid-19.MethodsIn platform trial therapeutic agents, we randomly assigned had Covid-19 without end-organ failure 1:1 ratio to receive either LY-CoV555 matching placebo. In addition, all received...
Abstract Advances in antiretroviral therapy (ART) have made it possible for persons with human immunodeficiency virus (HIV) to live a near expected life span, without progressing AIDS or transmitting HIV sexual partners infants. There is, therefore, increasing emphasis on maintaining health throughout the span. To receive optimal medical care and achieve desired outcomes, must be consistently engaged able access uninterrupted treatment, including ART. Comprehensive evidence-based primary...
Substance use is a major driver of the HIV epidemic and associated with poor care outcomes. Patient navigation (care coordination case management) financial incentives for achieving predetermined outcomes are interventions increasingly promoted to engage patients in substance disorders treatment care, but there little evidence their efficacy improving HIV-1 viral suppression rates.To assess effect structured patient intervention or without improve rates among elevated loads recruited as...
BackgroundSince the 1918 influenza pandemic, non-randomised studies and small clinical trials have suggested that convalescent plasma or anti-influenza hyperimmune intravenous immunoglobulin (hIVIG) might benefit for patients with infection, but definitive data do not exist. We aimed to evaluate safety efficacy of hIVIG in a randomised controlled trial.MethodsThis randomised, double-blind, placebo-controlled trial was planned 45 hospitals Argentina, Australia, Denmark, Greece, Mexico, Spain,...
Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible virus that can infect healthcare personnel (HCP) and patients in settings. Specific care activities, particular, aerosol-generating procedures, may have higher risk of transmission. The rapid emergence global spread SARS-CoV-2 has created significant challenges facilities, particularly with severe shortages personal protective equipment (PPE) used to protect HCP. Evidence-based...
In a randomized, placebo-controlled, clinical trial, bamlanivimab, SARS-CoV-2-neutralizing monoclonal antibody, given in combination with remdesivir, did not improve outcomes among hospitalized patients COVID-19 based on an early futility assessment.
Background: Levels of plasma SARS-CoV-2 nucleocapsid (N) antigen may be an important biomarker in patients with COVID-19 and enhance our understanding the pathogenesis COVID-19. Objective: To evaluate whether levels can predict short-term clinical outcomes identify viral factors associated hospitalized SARS-CoV-2. Design: Cross-sectional study baseline level from 2540 participants enrolled TICO (Therapeutics for Inpatients With COVID-19) platform trial August 2020 to November 2021,...
In the current mpox outbreak, infections are usually self-limited. We describe 3 patients with uncontrolled HIV and lasting months, causing debilitating lesions, complications, death, despite initiating anti-mpox antiretroviral therapy. Delayed treatment of antiviral agents may contribute to poor outcomes in severely immunocompromised patients.
In the Strategic Timing of Antiretroviral Treatment (START) study, immediate combination antiretroviral therapy (cART) initiation reduced cancer risk by 64%. We hypothesized that reduction was higher for infection-related and determined differences in CD4 cell counts human immunodeficiency virus (HIV) RNA between study arms. Incident malignancies START were categorized into infection-unrelated cancer. used Cox models to assess factors associated with both categories. sequential adjustment...
OBJECTIVE: Despite availability of highly effective direct acting antivirals (DAA), barriers in access to these therapies limit our ability achieve HCV eradication. We aim evaluate overall rates and predictors treatment across four community-based health-care systems focusing on race/ethnicity insurance-specific disparities. METHODS: retrospectively evaluated all adults with chronic at health care from 1 January 2011 28 February 2017, which included a large proportion ethnic minorities, two...
Background NRTI-sparing regimens may avoid long-term mitochondrial, bone and renal toxicities maintain viral suppression. Methods In the RADAR study, 85 antiretroviral-naïve HIV-infected patients were randomized to receive either raltegravir (RAL) (n = 42) or tenofovir/emtricitabine (TDF/FTC) 43), each with ritonavir-boosted darunavir (DRV/r). Virologic efficacy was assessed at weeks 24 48. Bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) scan baseline week 48, turnover...
Abstract Advances in antiretroviral therapy (ART) have made it possible for persons with human immunodeficiency virus (HIV) to live a lifespan approaching that of people without HIV, progressing AIDS or transmitting HIV sexual partners infants. There is, therefore, increasing emphasis on maintaining health throughout the lifespan. To receive optimal medical care and achieve desired outcomes, must be consistently engaged able access uninterrupted treatment, including ART. Comprehensive...
Abstract Background Persistent mortality in adults hospitalized due to acute COVID-19 justifies pursuit of disease mechanisms and potential therapies. The aim was evaluate which virus host response factors were associated with risk among participants Therapeutics for Inpatients (TICO/ACTIV-3) trials. Methods A secondary analysis 2625 SARS-CoV-2 infection randomized 1 5 antiviral products or matched placebo 114 centers on 4 continents. Uniform, site-level collection participant baseline...